BioSpace News Archive

Transcenta Holding Limited announces that two posters for clinical trials of its ADCC enhanced anti-CLDN18.2 monoclonal antibody Osemitamab in combination with CAPOX or CAPOX plus Nivolumab for first-line G/GEJ cancer will be presented at 2023 American Society of Clinical Oncology Annual Meeting.

Masimo announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicine programs.

Immuron Limited is pleased to announce that the US Naval Medical Research Center has received approval from the US Food and Drug Administration to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli developed in collaboration with Immuron.

Neuro3 Therapeutics announced the signing of an exclusive, worldwide license and option agreement with Lundbeck, a leading pharmaceutical company focusing on the development of innovative medicines treating neurological and psychiatric diseases.

NYU Langone Health and Brown University’s School of Public Health announced a grant award from the National Institute on Drug Abuse, part of the National Institutes of Health, to conduct research to measure the impact of some of the first publicly recognized overdose prevention centers in the United States, located in New York City and Providence, Rhode Island.

HAPPE Spine announces that the company’s INTEGRATE-C™ Interbody Fusion System has received 510k clearance from the FDA.

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, May 11, 2023.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the following upcoming investor conferences:

VanDeMark Chemical, Inc., a leading global producer of life science chemistries, announced the appointment of Dr. Boudewijn van Lent as President and CEO, effective immediately.

Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced an upcoming poster presentation at IMMUNOLOGY2023™.